In­trex­on taps new COO, CBO in ex­ec­u­tive reshuf­fle; De­nali tar­gets up to $182M in IPO

→ An­oth­er round of lead­er­ship changes is tak­ing place at In­trex­on $XON: re­tired lieu­tenant gen­er­al Thomas Bo­stick is slat­ed to re­place COO An­drew Last; Te­va vet Nir Nim­ro­di has been pro­mot­ed as chief busi­ness of­fi­cer; and He­len Sabze­vari is tak­ing the helm of Pre­ci­gen as pres­i­dent of the sub­sidiary. This marks the lat­est move by hands-on bil­lion­aire backer and CEO Ran­dal “RJ” Kirk, af­ter the high pro­file de­par­ture of then-pres­i­dent Gene Ger­mano in March. “A more stream­lined se­nior man­age­ment struc­ture is in line with our tran­si­tion to a group of re­lat­ed and in­creas­ing­ly com­mer­cial­ly ori­ent­ed en­ter­pris­es,” Kirk said in a state­ment.

De­nali is eye­ing a price be­tween $17 and $19 per share for its IPO, bump­ing the max­i­mum take to $182 mil­lion for a to­tal of 8,333,333 shares that they are sell­ing. That’s up from the $100 mil­lion the start­up had pen­cilled in ear­li­er this month, though they are es­ti­mat­ing a more mod­est $136 mil­lion, ac­cord­ing to the amend­ed S-1. As pre­vi­ous­ly an­nounced, the neu­rode­gen­er­a­tion-fo­cused biotech will list on NAS­DAQ as $DNLI. At the end of Sep­tem­ber, it had $190.8 mil­lion in cash, cash equiv­a­lents and mar­ketable se­cu­ri­ties. The ex­tra cash will help move De­nali’s six core and five seed pro­grams for­ward, the most ad­vanced of which is still in Phase I de­vel­op­ment.

Bay­er said over the hol­i­day week­end that its glob­al Phase III clin­i­cal study of Amikacin In­hale — in ad­di­tion to stan­dard of care in in­tu­bat­ed and me­chan­i­cal­ly ven­ti­lat­ed pa­tients with Gram-neg­a­tive pneu­mo­nia — flopped in com­par­i­son to stan­dard of care and aerosolized place­bo. Amikacin In­hale is the de­vel­op­ment name of an in­te­grat­ed drug-de­vice com­bi­na­tion, con­sist­ing of a spe­cial­ly for­mu­lat­ed Amikacin In­hala­tion So­lu­tion and a pro­pri­etary Syn­chro­nized In­hala­tion Sys­tem with a vi­brat­ing mesh neb­u­liz­er.

→ In a la­bel up­date for its he­mo­phil­ia B drug Al­pro­lix, Biover­a­tiv $BIVV is high­light­ing da­ta that shows the treat­ment to be ef­fec­tive in bleed pro­tec­tion among chil­dren as well as adults. The new la­bel, based on in­ter­im da­ta from the Phase III B-YOND tri­al and fi­nal da­ta from Kids B-LONG study, re­flects the re­sults of pro­phy­lac­tic treat­ment of 93 sub­jects for more than 104 weeks. Said EVP and chief glob­al ther­a­peu­tics op­er­a­tions of­fi­cer Roge­rio Vi­val­di: “Al­pro­lix has the most clin­i­cal tri­al ex­pe­ri­ence of any he­mo­phil­ia B ex­tend­ed half-life ther­a­py on the mar­ket, and in the three years since ap­proval, we have con­tin­ued to ob­serve low over­all bleed rates, as well as low spon­ta­neous and joint bleeds with ex­tend­ed pro­phy­lac­tic dos­ing across all pop­u­la­tions,” It’s not all rosy, though; among the up­dates is al­so ob­struc­tive uropa­thy as a com­mon ad­verse re­ac­tion to the drug.

Bris­tol My­ers is clean­ing up the post-Cel­gene merg­er pipeline, and they’re sweep­ing out an ex­per­i­men­tal check­point in the process

Back during the lead up to the $74 billion buyout of Celgene, the big biotech’s leadership did a little housecleaning with a major pact it had forged with Jounce. Out went the $2.6 billion deal and a collaboration on ICOS and PD-1.

Celgene, though, also added a $530 million deal — $50 million up front — to get the worldwide rights to JTX-8064, a drug that targets the LILRB2 receptor on macrophages.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

Is a pow­er­house Mer­ck team prepar­ing to leap past Roche — and leave Gilead and Bris­tol My­ers be­hind — in the race to TIG­IT dom­i­na­tion?

Roche caused quite a stir at ASCO with its first look at some positive — but not so impressive — data for their combination of Tecentriq with their anti-TIGIT drug tiragolumab. But some analysts believe that Merck is positioned to make a bid — soon — for the lead in the race to a second-wave combo immuno-oncology approach with its own ambitious early-stage program tied to a dominant Keytruda.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Fangliang Zhang, AP Images

UP­DAT­ED: Leg­end fetch­es $424 mil­lion, emerges as biggest win­ner yet in pan­dem­ic IPO boom as shares soar

Amid a flurry of splashy pandemic IPOs, a J&J-partnered Chinese biotech has emerged with one of the largest public raises in biotech history.

Legend Biotech, the Nanjing-based CAR-T developer, has raised $424 million on NASDAQ. The biotech had originally filed for a still-hefty $350 million, based on a range of $18-$20, but managed to fetch $23 per share, allowing them to well-eclipse the massive raises from companies like Allogene, Juno, Galapagos, though they’ll still fall a few dollars short of Moderna’s record-setting $600 million raise from 2018.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck wins a third FDA nod for an­tibi­ot­ic; Mereo tack­les TIG­IT with $70M raise in hand

Merck — one of the last big pharma bastions in the beleaguered field of antibiotic drug development — on Friday said the FDA had signed off on using its combination drug, Recarbrio, with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The drug could come handy for use in hospitalized patients who are afflicted with Covid-19, who carry a higher risk of contracting secondary bacterial infections. Once SARS-CoV-2, the virus behind Covid-19, infects the airways, it engages the immune system, giving other pathogens free rein to pillage and plunder as they please — the issue is particularly pertinent in patients on ventilators, which in any case are breeding grounds for infectious bacteria.

As it hap­pened: A bid­ding war for an an­tibi­ot­ic mak­er in a mar­ket that has rav­aged its peers

In a bewildering twist to the long-suffering market for antibiotics — there has actually been a bidding war for an antibiotic company: Tetraphase.

It all started back in March, when the maker of Xerava (an FDA approved therapy for complicated intra-abdominal infections) said it had received an offer from AcelRx for an all-stock deal valued at $14.4 million.

The offer was well-timed. Xerava was approved in 2018, four years after Tetraphase posted its first batch of pivotal trial data, and sales were nowhere near where they needed to be in order for the company to keep its head above water.

Drug man­u­fac­tur­ing gi­ant Lon­za taps Roche/phar­ma ‘rein­ven­tion’ vet as its new CEO

Lonza chairman Albert Baehny took his time headhunting a new CEO for the company, making it absolutely clear he wanted a Big Pharma or biotech CEO with a good long track record in the business for the top spot. In the end, he went with the gold standard, turning to Roche’s ranks to recruit Pierre-Alain Ruffieux for the job.

Ruffieux, a member of the pharma leadership team at Roche, spent close to 5 years at the company. But like a small army of manufacturing execs, he gained much of his experience at the other Big Pharma in Basel, remaining at Novartis for 12 years before expanding his horizons.

Covid-19 roundup: Ab­b­Vie jumps in­to Covid-19 an­ti­body hunt; As­traZeneca shoots for 2B dos­es of Ox­ford vac­cine — with $750M from CEPI, Gavi

Another Big Pharma is entering the Covid-19 antibody hunt.

AbbVie has announced a collaboration with the Netherlands’ Utrecht University and Erasmus Medical Center and the Chinese-Dutch biotech Harbour Biomed to develop a neutralizing antibody that can treat Covid-19. The antibody, called 47D11, was discovered by AbbVie’s three partners, and AbbVie will support early preclinical work, while preparing for later preclinical and clinical development. Researchers described the antibody in Nature Communications last month.

Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

So let’s say you’re running a cutting-edge, clinical-stage biotech, probably public, but not necessarily so, which could see some big advantages teaming up with some marquee researchers, picking up say $50 million to $75 million dollars in a non-threatening minority equity investment that could take you to the next level.

Doug Giordano might have some thoughts on how that could work out.

The SVP of business development at the pharma giant has helped forge a new fund called the Pfizer Breakthrough Growth Initiative. And he has $500 million of Pfizer’s money to put behind 7 to 10 — or so — biotech stocks that fit that general description.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

RA Cap­i­tal, Hill­house join $310M rush to back Ever­est's climb to com­mer­cial heights in Chi­na

Money has never been an issue for Everest Medicines. With an essentially open tab from their founders at C-Bridge Capital, the biotech has gone two and a half years racking up drug after drug, bringing in top exec after top exec, and issuing clinical update after update.

But now other investors want in — and they’re betting big.

Everest is closing its Series C at $310 million. The first $50 million comes from the Jiashan National Economic and Technological Development Zone; the remaining C-2 tranche was led by Janchor Partners, with RA Capital Management and Hillhouse Capital as co-leaders. Decheng Capital, GT Fund, Janus Henderson Investors, Rock Springs Capital, Octagon Investments all joined.